PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 96 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $610,015 | +132.8% | 58,825 | +221.4% | 0.02% | +114.3% |
| Q2 2023 | $262,070 | +57.9% | 18,301 | +22.4% | 0.01% | +16.7% |
| Q3 2022 | $166,000 | -40.9% | 14,955 | -55.1% | 0.01% | -53.8% |
| Q2 2022 | $281,000 | +35.1% | 33,343 | +432.5% | 0.01% | -40.9% |
| Q4 2020 | $208,000 | – | 6,262 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $40,675,000 | 10.18% |
| FRAZIER MANAGEMENT LLC | 5,827,415 | $114,625,000 | 8.82% |
| Abingworth LLP | 1,203,135 | $23,606,000 | 5.72% |
| RA Capital Management | 3,115,008 | $61,272,000 | 1.08% |
| Avidity Partners Management LP | 1,896,000 | $37,294,000 | 0.79% |
| StepStone Group LP | 422,085 | $8,302,000 | 0.47% |
| Summit Rock Advisors, LP | 34,100 | $671,000 | 0.40% |
| Parkman Healthcare Partners LLC | 77,481 | $1,524,000 | 0.34% |
| Rhenman & Partners Asset Management AB | 186,210 | $3,624,000 | 0.24% |
| Ikarian Capital, LLC | 74,560 | $1,467,000 | 0.22% |